Wolfe Research Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $27

Futu NewsMar 18 14:33

JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Hold Rating

Futu NewsMar 3 20:34

LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50

Futu NewsMar 1 03:32

Buy Rating for Spyre Therapeutics: Promising Pipeline and Strategic Advancements Drive Growth Potential

TipRanksMar 1 02:53

Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $65

Futu NewsFeb 28 22:34

Wedbush Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)

TipRanksFeb 28 21:55

BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $70

Futu NewsFeb 28 20:38

TD Cowen Maintains Spyre Therapeutics(SYRE.US) With Buy Rating

Futu NewsFeb 28 13:32

Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $71

Futu NewsFeb 10 21:31

BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $70

Futu NewsJan 21 21:31

Promising Expansion in Rheumatoid Arthritis Drives Buy Rating for Spyre Therapeutics

TipRanksJan 21 20:56

LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50

Futu NewsJan 14 22:33

Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating

Futu NewsJan 14 09:32

LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50

Futu NewsDec 18, 2024 06:31

BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $70

Futu NewsDec 18, 2024 03:31

Promising Potential of Spyre Therapeutics' SPY002 Drives Buy Rating Amid Robust Anti-TL1A Market

TipRanksDec 18, 2024 03:16

Spyre Therapeutics Analyst Ratings

BenzingaDec 11, 2024 19:32

JonesTrading Initiates Spyre Therapeutics(SYRE.US) With Hold Rating

Futu NewsDec 11, 2024 05:31

Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $71

Futu NewsNov 14, 2024 10:32

Baird Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $65

Futu NewsNov 13, 2024 20:36